Myeloma Patients Europe (MPE) joins project consortium looking at the role of innovative CAR-T immunotherapy in multiple myeloma
Today marks the official launch of a new international project consortium, known as “CARAMBA”, which will research an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide-range of stakeholders, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory through to multiple myeloma patients in the clinic.